Author

Jan-Dietert C. Brugma

Observed names: Brugma, Jan-Dietert, J.C. Brugma, J.D. Brugma, JC Brugma, Jan Dietert Brugma, Jan-Dietert Brugma, Jan-Dietert C Brugma, Jan‐Dietert Brugma, Jan‐Dietert Christoffer Brugma

Institution: Erasmus MC

Observed institution: Erasmus MC

ORCID: 0000-0001-6124-8825

Observed ORCID: 0000-0001-6124-8825

OpenAlex ID: A5084093020

Drug–drug interactions in patients treated for cancer: a prospective study on clinical interventions

2015 · R.W.F. van Leeuwen, F.G.A. Jansman, et al. · Annals of Oncology · 144

PDF

High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa

2010 · Juna M. de Vries, Nadine A.M.E. van der Beek, et al. · Molecular Genetics and Metabolism · 106

Manipulation of oral medication for children by parents and nurses occurs frequently and is often not supported by instructions

2019 · Anna C. van der Vossen, Linda Al‐Hassany, et al. · Acta Paediatrica · 39

PDF

First experience with enzyme replacement therapy during pregnancy and lactation in Pompe disease

2011 · Juna M. de Vries, Jan-Dietert C. Brugma, et al. · Molecular Genetics and Metabolism · 33

Availability of age-appropriate paediatric formulations in the Netherlands: the need in daily clinical practice remains

2019 · Anna van der Vossen, Sandra Buljaç, et al. · European Journal of Hospital Pharmacy · 17

PDF

Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices

2023 · Aniek Dane, Anne-Sophie Klein Gebbink, et al. · Applied Health Economics and Health Policy · 7

PDF

Digital Outcome Measurement to Improve Care for Patients With Immune-Mediated Inflammatory Diseases: Protocol for the IMID Registry

2023 · Agnes E M Looijen, Reinier C A van Linschoten, et al. · JMIR Research Protocols · 4

PDF

Stability of alglucosidase alfa in 0.9% sodium chloride for enzyme replacement therapy in patients with Pompe disease: insights from enzyme activity and cellular uptake measurements

2025 · Ina Barzel, Jan-Dietert C Brugma, et al. · European Journal of Hospital Pharmacy · 2

PDF

Variability in anthracycline dose conversions and cardiotoxicity monitoring: insights from hospital pharmacists on institutional protocols in oncology practice

2026 · Sheraz A. Ditta, Franny Jongbloed, et al. · Supportive Care in Cancer · 1

PDF

Impact of the First SARS-CoV-2 Lockdown on Adherence to Biological Treatment in Patients with Immune-Mediated Inflammatory Diseases in the Netherlands

2023 · Romy van der Groef, Pascal HP de Jong, et al. · Patient Preference and Adherence · 1

PDF

The impact of medication shortages on paediatric care: A retrospective impact analysis

2026 · Maaike Johanna Rutten ‐ van Kranenburg, Laurens Christiaan van Rijn, et al. · British Journal of Clinical Pharmacology

Leveringszekerheid van medicatie blijft een politiek hoofdpijndossier

2026 · de Leeuw, Sander, Dullaert, Wouter, et al. · Socio-Environmental Systems Modeling

Response to: Correspondence on ‘Stability of alglucosidase alfa in 0.9% sodium chloride for enzyme replacement therapy in patients with Pompe disease: insights from enzyme activity and cellular uptake measurements’ by Barzel et al

2025 · Ina Barzel, Jan Dietert Brugma, et al. · European Journal of Hospital Pharmacy

PDF

6ER-028 Market exclusivity expiry has limited effect on prices of brand-name orphan drugs

2022 · A Dane, A Klein Gebbink, et al.

PDF

P4.39 Enzyme replacement therapy during pregnancy and lactation in Pompe disease

2011 · J.M. de Vries, J.C. Brugma, et al. · Neuromuscular Disorders

Calculation of cumulative doses of anthracyclines: Cardiotoxicity demands action

2010 · Jan‐Dietert Brugma, R.R. Boedhram, et al. · Pharmaceutisch Weekblad

Works count: 16

Citation count: 354

H-index: 6

I10-index: 5